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Abstract
The inhibitors of cyclin-dependent kinase (CDK) 4 (INK4) bind CDK4/6 to prevent their 
association with D-cyclins and G1 cell cycle initiation and progression. We report here that among 
the seven CDK inhibitors, p18INK4c played an important role in modulating TCR-mediated T cell 
proliferation. Loss of p18INK4c in T cells led to hyperproliferation in response to CD3 stimulation. 
p18INK4c-null mice developed lymphoproliferative disorder and T cell lymphomas. Expression of 
IL-2, IL-2R-a, and the major G1 cell cycle regulatory proteins was not altered in p18-null T cells. 
Both FK506 and rapamycin efficiently inhibited proliferation of p18-null T cells. In activated T 
cells, p18INK4c remained constant, and preferentially associated with and inhibited CDK6 but not 
CDK4. We propose that p18INK4c sets an inhibitory threshold in T cells and one function of CD28 
costimulation is to counteract the p18INK4c inhibitory activity on CDK6-cyclin D complexes. The 
p18INK4c protein may provide a novel target to modulate T cell immunity.
Quiescent (G0) T cells respond to Ag stimulation by entering into cell cycle, producing 
cytokine, and undergoing clonal expansion. Signal transduction pathways leading to 
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cytokine (IL-2) induction have been extensively studied (1, 2). Efficient activation of 
quiescent T cells requires two signals (3, 4). The primary signal involves the TCR to interact 
with specific Ags in the MHC complex on APCs. The major costimulatory molecule is 
CD28 on T cells, which interacts with the B7.1 or B7.2 molecules on APC. TCR activation 
leads to activation of nonreceptor tyrosine kinases such as lck, fyn, and ZAP70 that activate 
the NFATc via phospholipase Cγ1 and calcineurin, and induction of the Fos/Jun (AP1) 
transcription factor via the Ras and mitogen-activated protein kinase pathway (1, 5). 
Activated NFATc and AP1 bind to the IL-2 promoter to induce IL-2 expression. The CD28-
specific signaling pathway is not well defined, probably involving activation of the 
phosphatidylinositol 3 kinase and Akt kinase pathway (6, 7), the Rho family GTPase Rac, 
and NF-KB (8). CD28 costimulation enhances the TCR-mediated signals in IL-2 expression 
by enhancing the stability of the IL-2 mRNA as well as IL-2 transcription. Blocking of 
CD28 costimulation suppresses T cell proliferation and induces unresponsiveness and cell 
death (9).
Relatively less is known about how the G0/G1 cell cycle regulatory molecules function 
during T cell activation. IL-2-mediated mitogenic signaling has been suggested to lead to 
clonal expansion of activated T cells (10, 11) and Stat5a/b are required for IL-2-induced cell 
cycle progression of peripheral T cells (12). However, IL-2-independent cell proliferation 
induced by TCR and CD28 costimulation has also been reported (13). Entry of quiescent 
(G0) cells into G1 phases of the cell cycle involves induction of a number of cell cycle 
activators, including cyclin-dependent kinases (CDKs)4 4/6 and D-type cyclins. Activation 
of cyclin D-CDK4/6, in conjunction with subsequent activation of cyclin E-CDK2, results in 
phosphorylation of members of retinoblastoma product family proteins and progression 
through the G1 phase of the cell cycle (14–16). Mammalian CDKs are also negatively 
regulated by CDK inhibitors (17). Currently, seven CDK inhibitors have been identified in 
mammalian cells. They consist of two distinct multigene families that differ in both structure 
and mechanism of action. Members of the CIP/KIP family (p21CIP1, p27KIP1, and p57KIP2) 
inhibit activity of all CDKs by forming a ternary complex with cyclin-CDK, whereas 
members of the INK4 family (p16INK4a, p15INK4b, p18INK4c, and p19INK4d) specifically 
inactivate CDK4 and CDK6 activity by forming a binary INK4-CDK4/6 complex (17). 
Thus, CDK4/6 are regulated by both families of CDK inhibitors and by mitogen-induced D-
cyclins, and may serve as integrators for various signaling pathways of G1 cell cycle control.
In T cells, CDK4/6 and D-type cyclins are induced by T cell activation via TCR and CD28 
costimulation (13, 18, 19), or by chemical or growth factor stimulations (20–22). Cyclin D3 
has been reported to be the major inducible D-type cyclin in T cells (19, 21, 23, 24). Among 
the CIP/KIP family of CDK inhibitors, p21 (25) and p57 (26) are not significantly expressed 
in lymphoid organs, and mutations of the genes show no effect on T cell proliferation. 
Induction of p21 during T cell activation has recently been reported, and autoimmune 
diseases develop in old female mice (27). p27 is preferentially expressed in lymphoid organs 
and cells (28, 29). T cell activation with mitogens and IL-2 leads to a decrease of steady-
state p27 level in T cells (30, 31) and to a higher rate of proliferation of p27-deficient mouse 
T cells and thymocytes (32). Thus, a potential role of p27 in the negative modulation of T 
cell proliferation has been proposed. However, other studies report that p27-deficient mouse 
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peripheral T cells from the spleen or lymph node (LN) show normal proliferation in 
response to CD3/CD28 stimulation (33) or to CD3/IL-2 stimulation (34). These discrepant 
reports indicate that the role of p27 in modulating TCR-mediated T cell proliferation is 
unclear at present. A recent report has implicated p27 in the induction of T cell 
unresponsiveness to stimulation (T cell anergy, Ref. 35). Therefore, although not directly 
involved in regulating initial T cell clonal expansion, p21 and p27 may be involved in 
modulating some aspects of T cell immunity.
Of the four INK4 CDK inhibitors, p16INK4a expression is not detected and p15INK4b is 
expressed at low levels in lymphoid organs (36). The p18INK4c and p19INK4d genes are both 
highly expressed in lymphoid organs/cells (37–42). Inactivation of p15INK4b was recently 
shown to have little or no significant effect on T cell proliferation (43). In B lymphocytes, 
p19 is induced after B cell activation (44), and T cells with a mutant p19 allele show normal 
T lymphocyte proliferation (45). In addition to expression in lymphoid organs, a role of p18 
in regulating T cell proliferation is also suggested by the observations that mice lacking p18 
develop enlarged lymphoid organs and that p18-deficient lymphocytes show increased 
proliferation to lectin-mediated stimulation (43, 46).
We report here that the p18-deficient T cells were hyperproliferative in response to TCR 
stimulation in the absence or presence of CD28 costimulation. These findings establish a 
role of p18 in modulating TCR-mediated T cell proliferation, and we suggest that one 
important function of CD28 costimulation (or strong stimulation signals) is to antagonize the 
p18 function. T cells lacking p27 or p19 exhibited normal levels of T cell proliferation after 
activation with CD3 and CD28, indicating a specificity of p18 in the modulation of T cell 
proliferation. Although anti-CD3 mAb treatment induced efficient expression of CDK4/6, 
full induction of cyclin D3 required CD28 costimulation. During activation of T cells, the 
level of p18 proteins remained constant. Induction of CDK4/6 correlated with an increase of 
p18-CDK6 complex but not p18-CDK4 complex. In p18-null T cells activated with anti-
CD3, CDK6- but not CDK4-associated kinase activity was elevated over wild-type (WT) 
controls. Our results suggest a model in which p18 functions as an inhibitory threshold in 
quiescent T cells and modulates proliferation of T cells.
Materials and Methods
Mutant mice and reconstituted SCID mice
WT and p18-null mice were maintained as described (46). Littermates or age-matched mice 
(2–3 mo of age) were used in each experiment. For T cell lymphoma development, age-
matched WT or p18-null mice with similar genetic breeding history were kept in 
microisolator cages for 12–18 mo and analyzed for different types of tumors. T cell 
lymphomas were defined as T cell tumors in multiple organs including the LNs, spleen, and 
liver, and by histopathology. The tumor cells were analyzed by FACS for T and B cell 
markers.
To reconstitute T cells in SCID mice, WT or p19-null fetal liver cells from 14-day-old 
embryos (or WT and p18-null bone marrow cells) were injected into irradiated scid/scid 
CB17 mice (0.5 × 106 fetal liver cells or 2 × 106 bone marrow cells per mouse) as described 
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(47). LN T cells in the reconstituted mice were harvested at 8 wk post reconstitution, and 
standard T cell proliferation assays were performed. Normal T cell reconstitution was 
observed with p19-null fetal liver cells or with p18-null bone marrow cells (data not shown). 
No significant number of T cells is recoverable from nonreconstituted SCID mice.
Abs and FACS assays
Monoclonal Abs used for immunofluorescence staining include hamster anti-mouse CD3-
FITC (500-A2), rat anti-mouse CD4-FITC (CT-CD4), and rat anti-mouse CD25 IL-2R-PE 
(PC61 5.3) (Caltag Laboratories, Burlingame, CA). LN cells were stained and analyzed on a 
FACScan flow cytometer (BD Biosciences, Mountain View, CA). Nonviable cells were 
excluded by propidium iodide staining and light scatter profiles. The FACS data were 
analyzed with Cyclops 2000 version 4 data analysis software (Cytomation, Fort Collins, 
CO).
LN T cell preparation, activation, and proliferation assays
Complete medium (RPMI 1640 supplemented with 10% FCS, 2 mM L-glutamine, 50 U/ml 
penicillin, and 50 μg/ml streptomycin) was used for cell preparation and culture. Cervical, 
umbilical, and axial LNs from each mouse were harvested and pooled. CD3+ T cells were 
purified by negative enrichment (B220 depletion) with Immuno-columns (Biotex 
Laboratories, Edmonton, Canada) according to manufacturer’s protocol. For stimulation, T 
cells (2 × 106 total LN cells or 8 × 105 purified CD3+ cells) were stained with 100 μl of anti-
CD3 (0.2 μg/ml) alone or in combination with anti-CD28 (1 μg/ml) for 30 min on ice. Total 
LN cells (5 × 105) (or 2 × 105 purified CD3+ T cells) were added to plates coated with goat 
anti-hamster Ab (50 μg/ml; Caltag Laboratories). Cells were incubated at 37°C for 36 h and 
pulsed for 12 h with 1 μCi [3H]thymidine (NEN, Boston, MA) per well. All assays were 
performed in triplicate. Student’s t test was used for the statistical analysis.
Various concentrations of rapamycin and FK506 were added to activated T cell cultures. For 
the anti-CD3 titration assay, LN cells were plated in wells previously coated with different 
concentrations of anti-mouse CD3 mAb as described (48).
CD25 expression and IL-2 production assay
LN T cells were unstimulated, stimulated with either anti-CD3 alone, or stimulated with 
both anti-CD3 and anti-CD28 in triplicate wells. The IL-2 level in the culture supernatant 
were measured by an ELISA kit at 12 and 24 h poststimulation (BioSource International, 
Camarillo, CA). The LN T cells were also analyzed for CD25 expression (by FACS) and for 
proliferation by [3H]thymidine incorporation.
Western, immunoprecipitation (IP)-Western blot, and IP-kinase assays
Antisera for p18, p27, CDK2, CDK4, CDK6, and tubulin have been previously described 
(46, 49). IP, immunoblotting, and IP-kinase assay procedures were performed as described 
previously (46, 50, 51). LN cells from age-matched WT or p18−/− (null) mice were pooled 
and stimulated with anti-CD3, anti-CD28, or both. Cells treated with either no Ab or a low 
concentration of anti-CD3 (~1 ng/106 cells) that did not induce activation in either WT or 
p18-null cells (data not shown) were used as negative controls. Cells were activated as 
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described above and harvested at 36 h post activation for biochemistry assays. Protein 
concentrations were determined by the Bradford assay and equal amounts of proteins were 
used for each experiment. T cell activation was confirmed by measuring [3H]thymidine 
incorporation and CD25 expression. The kinase activity was quantified by a 
PhosphorImager with ImageQuant 5.0 software (Molecular Dynamics, Sunnyvale, CA). 
Densitometry was used for quantifying Western blots with NIH Image 1.61 software.
Results
Hyperproliferative responsiveness of p18-null T cells to TCR stimulation
Mice lacking p18 develop enlarged lymphoid organs, and p18-deficient lymphocytes exhibit 
an increased proliferation rate in response to lectin stimulation (46). We further investigated 
the role of p18 in modulating T cell proliferation in response to TCR-mediated activation. 
We demonstrated that activation of TCR with the anti-CD3 mAb led to hyperproliferation in 
the absence of CD28 costimulation (Fig. 1). LN T cells from WT mice showed low or no 
detectable levels of proliferation when activated with only anti-CD3 mAb. However, LN T 
cells from p18-null mice efficiently incorporated [3H]thymidine when stimulated with the 
same concentrations of anti-CD3 mAb (3- to 5-fold over WT, Fig. 1). Costimulation with 
anti-CD3/CD28 mAbs led to proliferation of both WT and p18-null T cells, and p18-null T 
cells showed further enhanced proliferation than WT T cells (Fig. 1). Analysis of data from 
19 independent experiments with 43 mice of each genotype showed that p18-null T cells 
consistently exhibited an average of 4-fold higher rate of proliferation than the WT T cells in 
response to anti-CD3 stimulation (Fig. 1B, p < 0.0005). Under the condition of 
costimulation with anti-CD3 and anti-CD28 mAbs, p18-null T cells still proliferated at an 
average of 2-fold higher rate than the WT T cells ( p < 0.05). Therefore, p18-deficient LN T 
cells responded to TCR (anti-CD3) stimulation more efficiently than WT T cells. This 
suggests that one of the costimulation functions of CD28 in T cells may be to counteract the 
inhibitory activity of p18.
Although the majority of total LN cells are T lymphocytes, lymphocytes from LNs also 
contain a small percentage of B cells. To show that the hyperproliferation is intrinsic to p18-
null T lymphocytes, we purified the CD3+ T cells from WT or p18-null LNs by negatively 
depleting B cells. Their proliferation rate in response to anti-CD3 stimulation and anti-CD3/
anti-CD28 costimulation was determined. Consistent with the results obtained from total LN 
lymphocytes, a higher rate of T cell proliferation was seen in p18-null CD3+ T cells in 
response to anti-CD3 stimulation or to costimulation with anti-CD3 and anti-CD28 (Fig. 
1C). Therefore, the p18-null T cells are intrinsically hyperproliferative in response to 
stimulation via their TCRs.
p18 plays an important role in the modulation of T cell proliferation
T cell activation with mitogens and IL-2 leads to a decrease of steady-state p27 level in T 
cells (30, 31) and to a higher rate of proliferation of p27-deficient mouse T cells and 
thymocytes (32). Thus, a potential role of p27 in the negative modulation of T cell 
proliferation has been implicated. However, other reports show that p27-deficient mouse 
peripheral T cells from the spleen or LN proliferate normally in response to CD3/CD28 
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stimulation (33) or to CD3/IL-2 stimulation (34). We tested the proliferation of p27-null LN 
T cells and showed that WT and p27-null T cells proliferated at the same levels in response 
to CD3 stimulation or to CD3/CD28 costimulation (Fig. 1D).
The p19 gene, like p18, is highly expressed in lymphoid cells/tissues (38–41). We generated 
two lines of p19-null mice with a p19 mutation that deleted a larger portion of the p19 
coding region than the one reported with an insertion mutation (45) and resulted in lethality 
in homozygous embryos at 12–14 days postgestation (M. Nicholas and Y. Xiong, 
unpublished data). To further confirm the specificity of p18 in modulating T cell 
proliferation, we derived T cells from scid/scid mice reconstituted with the p19-null and WT 
littermate fetal liver cells and tested for their proliferation responses to anti-CD3 or anti-
CD3/CD28 stimulation. In contrast to the p18-null T cells, there was no detectable increase 
of proliferation of reconstituted p19 mutant T cells in response to either CD3 alone or CD3/
CD28 costimulation (Fig. 1E). To control for the effect of SCID reconstitution on T cells, 
bone marrow cells from WT or p18-null mice were also used to reconstitute scid/scid mice 
to derive T cells that were similarly analyzed. Consistent with previous studies with T cells 
directly isolated from p18-null mice, reconstituted p18-null T cells showed 
hyperproliferative responses to either CD3 single stimulation or CD3/CD28 costimulation 
(Fig. 1F). These results, together with the lack of any detectable effect on TCR-mediated T 
cell proliferation by the loss of p21 (52, 53), p57 (54), and p27 (Refs. 33 and 34 and Fig. 
1D), indicate the specificity of p18 as a unique CDK inhibitor in regulating peripheral T cell 
proliferation in response to TCR stimulation.
Lymphoproliferative disorder and T cell lymphomas in old p18-null mice
Consistent with hyperproliferation of p18-null T cells, p18-null mice developed 
lymphoproliferative disorders illustrated by enlarged secondary lymphoid organs (Fig. 2A, 
spleen) (46). In the spleen, expansion of the white pulp was largely confined to the 
periarteriolar lymphatic sheaths (indicated by arrows in Fig. 2C). A small number of p18-
null mice (3 of 24, 12%) at 12–18 mo of age developed T cell lymphomas in multiple organs 
including the LNs, spleen, and liver. None of the age-matched WT control mice observed in 
the same period developed lymphomas (n = 20). Histopathology analysis of the lymphomas 
revealed massive lymphocytic infiltration of the liver, LNs, and spleen with effacement of 
normal architecture. The lymphomas were composed of monomorphic lymphocytes with 
irregularly oval nuclei, a single, often central nucleolus, finely clumped chromatin, and scant 
cytoplasm (Fig. 2D, and data not shown). Most cells from the p18-null lymphoma tissues 
expressed the CD3 marker (>90% T cells) indicating their T cell origin (Fig. 2E). 
Development of T cell lymphomas is consistent with the increased cellularity of T 
lymphocytes in p18-null mice and with their hyperresponsiveness to TCR stimulation (Fig. 
1), and suggests a role of p18 in suppressing T cell lymphoma development. Compared with 
development of pituitary tumors in the intermediate lobe observed in the majority of p18 
mutant mice (43, 46), the development of T cell lymphomas occurred at a lower frequency 
and in older animals. The low penetrance suggests that additional genetic mutation(s) is 
required to collaborate with the p18 loss in the development of T cell lymphomas.
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p18-null T cells show normal expression of IL-2 and IL-2Rα
IL-2-mediated mitogenesis has been suggested to play a major role in T cell proliferation 
after activation (10, 12). To test the possibility that elevated expression of IL-2 and/or IL-2 
receptors may contribute to the hyperproliferation of p18-null T cells in response to CD3-
mediated signaling, we analyzed expression of the high-affinity IL-2R-a (CD25) and IL-2 
production in LN T cells. Freshly isolated LN cells or LN cells from WT and p18 mutant 
mice cultured in the absence of Ab stimulation showed similarly low levels of CD25 
expression (Fig. 3A, top panels, and data not shown). When activated with either CD3 alone 
or with both CD3 and CD28 Abs, no significant differences were observed between WT and 
p18-null T cells for CD25 expression at 12 or 24 h post stimulation (Fig. 3A). Similarly, 
IL-2 production with either CD3 or with both CD3 and CD28 mAbs was the same for WT 
and p18-null T cells (Fig. 3B). The same WT or p18-null cells were also tested for 
proliferation, and p18-null T cells proliferated efficiently in response to CD3 stimulation 
despite low levels of IL-2 production (data not shown).
Both FK506 and rapamycin efficiently inhibit p18-null T cell proliferation
CD28 costimulation appears to be required to counteract the p18 activity for efficient T cell 
proliferation. TCR-mediated signaling pathway via the Ca2+-dependent (calcineurin) NFAT 
activation and IL-2 expression can be inhibited by FK506 (1, 55), and IL-2-induced 
proliferation is sensitive to rapamycin (31, 56, 57). When tested, either FK506 or rapamycin 
efficiently inhibited the proliferation of both WT and p18-null T cells (Fig. 3C). Therefore, 
TCR-mediated signaling via calcineurin is essential for the proliferation of both WT and 
p18-null T cells. The rapamycin-sensitive IL-2 signaling pathways are also required for the 
proliferation of p18-null T cells.
Expression of G1 regulatory proteins in p18-null T cells is unchanged
To define the biochemical mechanism of p18-null T cell hyperproliferation, we examined 
the induction of three major G1 CDKs (CDK2, CDK4, and CDK6), the major D-type cyclin 
induced in T cells (cyclin D3), and CDK inhibitor p27KIP1, during activation of WT and 
p18-deficient LN T cells (Fig. 4). Anti-CD3 alone, as well as anti-CD3/CD28 costimulation, 
efficiently induced expression of CDK2, CDK4, and CDK6, and a significant degradation of 
p27. However, cyclin D3 was only induced weakly by anti-CD3 stimulation. Costimulation 
with anti-CD28 resulted in a 4-fold increase of cyclin D3 than anti-CD3 alone (Fig. 4 and 
data not shown). These results indicate that whereas the expression of G1 CDK proteins is 
primarily controlled by anti-CD3 (TCR) pathway, the expression of cyclin D3 is regulated 
by both anti-CD3 and anti-CD28 signaling pathways and may be required to counteract the 
p18 inhibitory activity in T cells. The expression patterns of these five G1 regulatory 
proteins were consistent with published results and indistinguishable between the WT and 
p18-deficient T cells. These results suggest that loss of p18 did not affect the expression and 
steady levels of CDK2, CDK4/6, cyclin D3, and p27.
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The p18 protein remains constant during T cell activation, and is associated with and 
inhibitory to CDK6 but not CDK4 in activated T cells
We next examined the steady-state level of p18 during T cell activation. Freshly isolated LN 
T cells or LN T cells cultured in the absence of stimulation showed very low levels of CDK4 
and CDK6, and high levels of p27 (Figs. 4 and 5A, lanes 1 and 2). In LN cells activated with 
anti-CD3 and anti-CD28, both CDK4 and CDK6 were induced and p27 was degraded (Fig. 
5A, lane 3). However, the level of p18 was not significantly altered after T cell activation 
(Fig. 5A).
When its association with CDK4 or CDK6 was analyzed by coimmunoprecipitation, we 
found that p18 was preferentially associated with CDK6 in activated T cells (Fig. 5, B and 
C). Only a minor amount of p18 was detected in association with CDK4 in resting or 
activated T cells (Fig. 5B, left panel and C, lowest left panel) despite readily detectable 
levels of CDK4 and p18 (Fig. 5, B and C). Preferential association of p18 with CDK6 in 
vivo is consistent with previous findings that p18 has higher affinity for CDK6 than CDK4 
in vitro (37). The band below the CDK6 band in the anti-CDK6 IP (Fig. 5C, upper right 
panel), although running close to the same size as CDK4, is not related to CDK4 because it 
was not detected with the anti-CDK4 Ab (data not shown).
When the kinase activity of CDK4 and CDK6 was analyzed, we found that CDK4 activity in 
WT T cells was efficiently induced by CD3 stimulation alone, and full activation by CD3 
and CD28 costimulation showed no further enhancement (Fig. 6A). The slight reduction of 
CDK4 activity in p18-null T cells after CD3 stimulation was not consistently observed. 
Consistent with lack of significant p18 association with CDK4 (Fig. 5), p18-null T cells 
showed no increased CDK4 activity either stimulated with CD3 or costimulated with CD3 
and CD28 (Fig. 6A). In contrast, the kinase activity of CDK6 in WT T cells was only weakly 
induced by CD3 stimulation, and full induction of CDK6 activity required CD3 and CD28 
costimulation (Fig. 6B). Consistent with its preferential association with p18, p18-null T 
cells activated with anti-CD3, at a concentration that induced proliferation of p18-null but 
not WT T cells, displayed a 3-fold increase of elevated CDK6 kinase activity over WT T 
cells (Fig. 6C). Like unstimulated T cells, WT or p18-null T cells stimulated with low 
concentrations of anti-CD3 (that did not induce either WT or p18 mutant T cell 
proliferation) showed no significant induction of CDK6 activity and no proliferation (Fig. 
6C and data not shown). A slight but reproducible reduction of CDK6 activity in p18-null T 
cells after CD3/CD28 costimulation was observed, but its significance on T cell proliferation 
was not clear.
Discussion
We report here that among the seven CDK inhibitor genes, p18INK4c was uniquely involved 
in negatively modulating T cell-proliferative responses to TCR and CD28 costimulation. 
Loss of p18 in T cells reduced the requirement of CD28 costimulation for efficient T cell 
proliferation (Fig. 1). Lymphoproliferative disorder and lymphomas developed in old p18-
null mice (Fig. 2). Furthermore, our biochemical analyses of the G1 regulatory proteins 
indicated that p18 was stable and preferentially inhibitory to CDK6 but not CDK4 activity in 
activated T cells (Figs. 5 and 6). The data suggest that p18INK4c may set an inhibitory 
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threshold in resting T cells. One of the functions of CD28 costimulation is to overcome the 
p18 inhibitory threshold, probably by fully inducing cyclin D, which competes with p18 to 
form active CDK6-cyclin D complexes.
p18 is a CDK inhibitor involved in modulating T cell proliferation
The presence of seven distinct CDK inhibitor genes with apparently overlapping activity 
suggests that individual CDK inhibitor genes may function in specific cell types. Indeed, 
individual CDK inhibitors are expressed in tissue-specific fashions (58, 59). However, 
multiple CDK inhibitors are detected in the same cell types. For example, p18, p19, and p27 
are all highly expressed in lymphoid organs and lymphocytes (28–30, 38–40). Three lines of 
evidence support a specific and unique role of the p18 protein in modulating T cell 
proliferation. First, p18-null T cells exhibit hyperproliferative responses to anti-CD3 single 
stimulation and to anti-CD3/anti-CD28 costimulation (Fig. 1) or to nonspecific mitogen 
stimulation (46). Loss of p15 (or of both p15 and p18) in T cells has no significant (or 
further) effect on T cell proliferation to mitogenic activation (43). Although also highly 
expressed in lymphoid cells and tissues, loss of either p27KIP1 (Fig. 1D and Refs. 33, 34) or 
p19INK4d (Fig. 1E and Ref. 45) showed no detectable effects on T cell proliferation in 
response to TCR stimulation. The hyperproliferation of total p27-null thymocytes in 
response to CD3 and IL-2 stimulation (32) may indicate a different role of p27 in 
thymocytes from its role in mature peripheral T lymphocytes. Second, p18-null mice 
developed enlarged lymphoid organs and increased lymphocyte cellularity (Fig. 2 and Ref. 
46). Consistent with the hyperproliferative response of p18-deficient T cells, old p18-null 
mice developed lymphoproliferative disorders and T cell lymphomas (Fig. 2 and Ref. 43). 
Third, p18 was associated with CDK6 in T cells and loss of p18 resulted in elevated CDK6 
activity and T cell hyperproliferation (Figs. 5 and 6). Therefore, p18 is a unique CDK 
inhibitor involved in modulating proliferation of T cells in response to TCR stimulation.
Induction of CDK6 activity is correlated with T cell proliferation and is the major target of 
p18 in peripheral T cells
Quiescent T cells respond to efficient Ag stimulation by cell cycle entry (proliferation-
competence), cytokine production (Refs. 1, 2, and see introduction), and cell cycle 
progression (clonal expansion). Relatively little is known about how G0/G1 cell cycle 
regulatory molecules function during T cell activation. CDK4/6 and D-type cyclins are 
induced by T cell activation signals such as TCR and CD28 costimulation (13, 18, 19) or by 
chemical activation (21, 22, 60, 61). Stimulation with anti-CD3 alone leads to efficient 
induction of a number of G1 regulatory proteins, including CDK2, CDK4, and CDK6 (Fig. 4 
and Ref. 12). However, full induction of D-cyclins depended on TCR and CD28 
costimulation (Refs. 13, 18; and Fig. 4). This G0-G1 “cell cycle entry” step can occur 
independently of the IL-2 activity (10, 60), although CD3-induced CDK6 and D-cyclins 
appear to depend on Stat5a/b (12). It is conceivable that other cytokines that signal through 
Stat5a/b (62, 63) may also be involved. IL-2-mediated signaling is clearly required for the 
proliferation of p18-null T cells, because p18-null T cells produced WT levels of IL-2 and 
IL-2R (CD25), and showed normal sensitivity to FK506 or rapamycin (Fig. 3).
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To elucidate the biochemical mechanism of G0/G1 regulation during T cell activation, we 
conducted a comprehensive analysis of three families of G1 cell cycle regulatory proteins 
during T cell activation with anti-CD3 and/or anti-CD28 stimulation (Figs. 4 – 6). In LN T 
cells, all three G1 CDKs (CDK2, CDK4, and CDK6) and cyclin D3 were induced, although 
full induction of cyclin D3 required CD28 costimulation. Correlated with T cell 
proliferation, efficient induction of CDK6 (but not CDK4) kinase activity required CD28 
costimulation. p27 was significantly degraded and p18 remained unchanged in response to 
anti-CD3 alone and to anti-CD3/CD28 costimulation. Interestingly, p18 was preferentially 
associated with CDK6 in activated T cells. Only a minor amount of p18 was detected in 
association with CDK4 in T cells stimulated with CD3 or CD28 alone, or with both CD3 
and CD28, despite readily detectable levels of CDK4 and p18 (Fig. 5 and data not shown). 
Consistent with the p18-CDK6 complex, CDK6 kinase activity, but not CDK4 activity, was 
hyperelevated in p18-null T cells (Fig. 6). Therefore, the major target of p18 inhibition in 
primary T cells is CDK6. Interestingly, induction of CDK4 and CDK6 in T cells requires 
distinct signaling pathways because Stat5a/b are required for the induction of CDK6, but not 
CDK4, by anti-CD3 stimulation (12).
In cell lines, p18 has been detected in association with both CDK4 and CDK6 (24, 39, 49, 
64, 65), although p18 has higher affinity for CDK6 than CDK4 in vitro (37). In an Ag-
dependent T cell line, we showed that p18 was associated with both CDK4 and CDK6. After 
activation of the T cell line with anti-CD3 and anti-CD28 mAbs, there was an increase of 
p18-CDK6 complex and decrease of p18-CDK4 association coincident with CDK6 
induction (G. Kovalev and L. Su, unpublished results). The constitutively high levels of 
CDK4 in T cell lines cultured in vitro may have contributed to the detectable p18-CDK4 
complexes in cell lines.
Modulation of CDK6 activity and T cell proliferation by p18
Based on the T cell proliferation study and biochemistry of G1 regulatory proteins, we 
propose that p18 sets an inhibitory threshold in resting T cells to maintain a stable 
quiescence state and to ensure that only significant stimulation of T cells leads to cell cycle 
activation and clonal expansion. In addition, the presence of p18 in activated T cells can 
down-modulate their proliferation to prevent overreactive immune responses. TCR (anti-
CD3) signaling alone can induce expression of CDK4 and CDK6 proteins, but only low 
levels of cyclin D3 (Fig. 4 and data not shown), which are below the threshold to counteract 
the p18 activity for a proliferation response. Only in T cells coactivated with both TCR and 
CD28 can the p18 inhibition be overcome (by the full induction of D-cyclins, and CDK6). 
Loss of p18 removes the inhibitory threshold, allowing the assembly of stable, active CDK6-
cyclin D complexes after TCR stimulation. Therefore, modulation of the p18 activity in T 
cells may provide a way to modulate T cell immunity.
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Hyperproliferative responses of p18−/− T cells to TCR stimulation. A, Enhanced 
proliferation of p18−/− LN cells was observed in response to stimulation with anti-CD3 or to 
costimulation with anti-CD3 and anti-CD28 mAbs. LN T cells from each mouse were 
assayed in triplicate. Data are from one representative experiment with two mice of each 
genotype, and error bars indicate SD of the average between the two mice. LN T cells 
cultured without stimulation were used as background controls (Bkg). B, Data from 19 
independent experiments (43 mice of each genotype) are summarized. The average value 
obtained from WT T cells in each experiment is equalized to 1. The fold of increased 
proliferation of p18-null T cells is calculated. Anti-CD3 stimulation of p18−/− T cells led to 
a 4-fold hyperproliferation (p < 0.0005). Costimulation with anti-CD3/CD28 led to a 2.7-
fold enhanced proliferation of p18-null T cells (p < 0.05). Error bars indicate SE values (n = 
19). C, Enriched CD3+ T cells from WT and p18-null mice were used for the proliferation 
assays as described in A. The experiment was performed two times with similar results. D, 
Loss of p27 in T cells did not lead to hyperproliferation in response to TCR stimulation. LN 
T cells from p27 mutant or WT littermate mice were isolated and analyzed as above. Three 
independent experiments were performed with similar results. E and F, Loss of p19INK4d did 
not lead to TCR-mediated T cell hyperproliferation. T cells derived from SCID mice 
reconstituted with p19-null or WT fetal liver cells showed similar proliferation in response 
to anti-CD3 stimulation and anti-CD3/CD28 costimulation (E). Data with LN T cells from 
two reconstituted SCID mice are shown. SD values are shown as error bars. T cells derived 
from SCID mice reconstituted with p18-null bone marrow cells were hyperproliferative in 
response to TCR (anti-CD3) stimulation or CD28 costimulation (F). Shown are data from 
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triplicate samples with LN T cells from reconstituted SCID mice. SD values are shown as 
error bars.
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Lymphoproliferative disorder and T cell lymphomas in p18−/− mice. A, Enlargement of 
spleens from p18-null mice. Photographs of spleens of a WT or a p18−/− mouse (2-mo old) 
indicate their relative sizes. B and C, Hyperplastic white pulp in the p18-null spleen. 
Histology (stained with H&E) of the WT (B) and p18−/− (C) spleens shows enlarged T cells 
zone (periarteriolar lymphatic sheaths) (light blue area of follicles surrounding the center 
arterioles shown by arrows) in the p18-null spleen. D, Lymphomas in the p18 mouse. 
Histopathology of a spleen lymphoma from a 15-mo-old p18-null mouse shows effacement 
of red and white pulp with densely packed, monomorphic lymphocytes. E, Flow cytometric 
analysis of lymphocytes obtained from the lymphoma tissues. The cells were stained with 
anti-CD3 and anti-B220. The majority of the cells are T cells (94% CD3+ cells).
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Normal IL-2 production and IL-2 dependence of p18−/− T cells. A, Normal IL-2-Ra (CD25) 
expression in p18−/− T lymphocytes. LN cells from WT (left) and p18−/− (right) mice were 
unstimulated (background, upper panels), or activated with anti-CD3 (middle panels) or 
anti-CD3/CD28 (lower panels). CD25 expression was monitored at 12 and 24 h post 
activation. The experiments were repeated three times. B, Normal IL-2 induction in p18−/− T 
cells. Cells similarly stimulated as above were used for measuring IL-2 production (in 
picograms per milliliter) in the culture supernatant by ELISA. Data represent results from 
triplicate samples, and SD is shown as error bars. Three independent experiments were 
performed with similar results. C, Normal responses of p18-null T cells to inhibitors of T 
cell activation. LN T cells were costimulated with anti-CD3/anti-CD28 mAbs and cultured 
with various concentrations of FK 506 (left panel) and rapamycin (right panel). Two mice 
were used for each genotype. The SD is shown as error bars. The experiment was repeated 
three times with similar results.
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Normal induction of G1 cell cycle regulators in p18−/− T cells. LN T cells from WT or 
p18−/− (Null) mice were incubated without Ab activation (No Stim.), stimulated with anti-
CD3, anti-CD28, or both (CD3/CD28). Cells were harvested at 36 h post culture for Western 
blot assays with various Abs (labeled on the right). T cell activation was confirmed by 
measuring [3H]thymidine incorporation (data not shown). Equal amounts of protein from 
each sample were analyzed.
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p18 is stable and associated preferentially with CDK6 in T cells. A, Stable levels of p18 
during T cell activation. Total levels of CDK6, CDK4, p27, and p18 in freshly isolated LN T 
cells (lane 1) or cultured for 36h (5 × 106/ml) without (lane 2) and with (lane 3) CD3/CD28 
activation were determined by IP-Western blot analysis with specific Ab. B, Preferential 
association of p18 with CDK6 in activated T cells. Coimmunoprecipitation of p18 with 
CDK4 (lane 1) and CDK6 (lane 2) in CD3/CD28-activated T cells (from Fig. 5A) was 
performed. The IP pellets were immunoblotted with anti-CDK4 (top left), anti-CDK6 (top 
right), or anti-p18 Ab (bottom panels). C, Preferential association of CDK6 and p18 in 
primary T cells stimulated with anti-CD3 and/or anti-CD28 mAbs. LN T cells were cultured 
in the absence (lane 1) or presence of anti-CD3 (lane 2), anti-CD28 (lane 3), and both anti-
CD3 and anti-CD28 (lane 4). The cells were harvested at 36 h post activation and analyzed 
by IP (with Abs labeled on top of the panels) and Western blot (labeled on the left and right) 
assays. Densitometry results (mean density) are presented. ■, Level of p18 associated with 
CDK6 (bottom right panel); □, p18 associated with CDK4 (bottom left panel). The band 
below the CDK6 band in the CDK6 IP was not related to CDK4, because immunoblotting of 
the anti-CDK6 IP with the anti-CDK4 Ab did not detect this band.
Kovalev et al. Page 20














p18-null T cells activated with anti-CD3 showed enhanced CDK6 activity. A, Normal CDK4 
activity in p18-null T cells. WT or p18-null LN T cells were cultured without stimulation 
(unstimulated), stimulated with anti-CD3 mAb, or costimulated with anti-CD3 and anti-
CD28 mAbs (anti-CD3/CD28) for 36 h. The competing peptide (+) for the anti-CDK4 Ab 
was used as specificity control. The IP pellets were assayed for CDK4 kinase activity with 
recombinant GST-retinoblastoma product as substrates. PhosphorImager quantitation 
represents the relative activity of CDK4 in WT (□) and p18−/− cells (■). B, Full induction of 
CDK6 activity in T cells required CD3/CD28 costimulation. WT LN T cells were treated as 
in Fig. 6A, except an anti-CDK6 Ab was used for the IP-kinase assay. The competing 
peptide (+) for the anti-CDK6 Ab was used as specificity control. ■, Relative CDK6 activity 
as a result of PhosphorImager quantitation. C, Enhanced CDK6 kinase activity in CD3-
activated p18-null T cells. WT or p18-null LN T cells were cultured with low (anti-CD3 low 
= 1 ng/106 cells, no proliferation induced for either WT or p18-null T cells) or high (anti-
CD3 high = 2.5 ng/106 cells, induced proliferation of p18-null but not WT T cells) 
concentrations of anti-CD3, or stimulated with anti-CD3 and anti-CD28 mAbs for 36 h. 
CDK6 kinase activity assay was performed by IP of CDK6 as above. PhosphorImager 
quantitation is shown for WT (□) and p18−/− (■) T cells.
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